An interventional study of Dual-scopic pancreatic necrosectomy(DPN) in Pancreatitis, Pancreatitis, Acute Necrotizing and Pancreatic Diseases, sponsored by First People's Hospital of Hangzhou. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-23.
Sponsored by First People's Hospital of Hangzhou · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Pancreatitis, Acute Necrotizing with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Pancreatitis, Acute Necrotizing · China.
Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, this one is the 14th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2020, is one of 8 with no phase, and was the 11th registered.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
Browse Pancreatitis, Acute Necrotizing studies →6 of the 17 studies in Pancreatitis, Acute Necrotizing with a site in China are open now. Recruiting first, the newest first:
Zhejiang University · Sites in China
Ages 18–75
Chunling Jiang · Sites in China
Ages 18+
West China Hospital · Sites in China
Ages 18+
Almazov National Medical Research Centre · Sites in China, Russia
Ages 18+
The First Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 12 Pancreatitis, Acute Necrotizing studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 70 across 47 interventional studies indexed under Pancreatitis, Acute Necrotizing.
Median enrollment 135 across the 14 interventional studies, 200 across the 3 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 17 has an industry lead sponsor. The 10 most frequent:
First People's Hospital of Hangzhou is the lead sponsor of 73 studies on the registry; 28 are open to participants now.
First People's Hospital of Hangzhou has 2 studies filed under Pancreatitis, Acute Necrotizing — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatitis, Acute Necrotizing with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093996Almazov National Medical Research CentreEndoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis | 2026-12-01 |
| NCT07201246West China HospitalOrgan Dysfunction Changes in Acute Necrotizing Pancreatitis Patients With Sepsis Following Open Necrosectomy | 2026-12-30 |
| NCT06380842Chunling JiangOrgan Dysfunction Change in Acute Necrotizing Pancreatitis Patients With Sepsis After Open Necrosectomy | 2026-12-30 |
| NCT07080697Zhejiang UniversityA Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension | 2027-02-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies in Pancreatitis, Acute Necrotizing with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The LPN procedure is performed under general anesthesia. The transperitoneal access to peripancreatic space is via the gastro-colic ligament and greater omentum, effusion and pus is removed by laparoscopic forceps and suction. Laparoscopic cholecystectomy (LC) is performed during the LPN procedure on patients with indication.
The NPN procedure is followed by the standard retroperitoneal approach. After the catheter is exchanged over a guide wire and serially dilated up from 6F to 24F followed by Seldinger technique, the access track to the necrotic cavity is established. A nephroscope is inserted into the cavity through the track for debridement. Using forceps and suction, the peripancreatic solid necrotic tissue and pus is grasped and removed. A large-bore irrigating drain is left in the cavity, with continuous irrigation by warm normal saline solution at a rate of 100-125 ml/h after surgery.
75 studies on the registry are indexed under Pancreatitis, Acute Necrotizing; 20 are open to participants now.
This study's planned enrollment of 20 is below the median of 70 across 47 interventional studies indexed under Pancreatitis, Acute Necrotizing.
Browse Pancreatitis, Acute Necrotizing studies →First People's Hospital of Hangzhou is the lead sponsor of 73 studies on the registry; 28 are open to participants now.
Compared within Pancreatitis, Acute Necrotizing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pancreatitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment of Acute Severe Pancreatitis with DPN
Procedure: Dual-scopic pancreatic necrosectomy(DPN)
Treatment of Acute Severe Pancreatitis with DPN
Complication Rate
Proportion of patients with perioperative complications
Time frame: through study completion, an average of 24 weeks
Mortality
Proportion of patients dying in the perioperative period
Time frame: through study completion, an average of 24 weeks
Hospital stay
Length of hospital stay
Time frame: through study completion, an average of 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2020; primary completion for Dec 2025, 65 months later.
Of 20 interventional studies with no phase under Pancreatitis, Acute Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 36. This study's planned 65 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pancreatitis, Acute Necrotizing →
First People's Hospital of Hangzhou